Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regadenoson in Lung Transplantation
NCT03072589Phase 1Unknown
- Start
- Nov 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of regadenoson in ischemia-reperfusion injury (IRI). Primary endpoint: Patient tolerability of assigned dose and duration at Day 7. Status: unknown.
02
Drugs
regadenoson
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT03072589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03072589.